Fresenius Medical Care saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 90 to 94.
Here Are 3 Keys For Successful Stock Investing
IBD's unique rating tracks price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they launch their largest climbs.
Fresenius Medical Care has risen more than 5% past a 25.25 entry in a first-stage flat base, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
While earnings growth decreased in the company's most recently reported quarter from 62% to 25%, revenue rose 4%, up from -4% in the prior report.
The company earns the No. 4 rank among its peers in the Medical-Outpatient/Home Care industry group. BrightSpring Hlth Svcs is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
